CTLA4 and neoplasm: Conversely, administration of PPARγ agonist rosiglitazone, an approved drug for the treatment of type II diabetes, augmented CD8+ T cytotoxicity in a myeloid cell-dependent manner and increased tumor destruction in combination with CTLA4 antibody blockade and GVAX [237].